Pascal Soriot, the still-new chief executive officer of AstraZeneca, said Tuesday that he was changing the leadership lineup below his spot on the organizational chart.
When the music stopped, there were no chairs for Martin Mackay, president of research and development, and Tony Zook, executive vice president, global commercial. Their roles were eliminated and, as the company said in its statement, "Martin Mackay and Tony Zook will leave the company at the end of January."
AstraZeneca is based in the United Kingdom, but has one of three regional headquarters in Wilmington and a second facility in Newark, Del. The company is trying to adjust to the loss of revenue from high-profit drugs that now face generic competition.
“This new senior executive team structure, that draws heavily from the leadership talent within the company, enables us to bring an even sharper management focus to key pipeline assets, key brands and key markets, and helps us further accelerate decision-making,” Soriot said in a statement.
The full company statement is here and it says the new senior executive team is:
- Pascal Soriot Chief Executive Officer and Executive Director
- Simon Lowth Chief Financial Officer and Executive Director
- Mene Pangalos Executive Vice President, Innovative Medicines
- Bahija Jallal Executive Vice President, MedImmune
- Briggs Morrison Executive Vice President, Global Medicines Development
- Paul Hudson Executive Vice President, North America
- Ruud Dobber Executive Vice President, Europe
- Mark Mallon Executive Vice President, International
- David Smith Executive Vice President, Operations & IS
- Lynn Tetrault Executive Vice President, Human Resources & Corporate Affairs
- Katarina Ageborg Chief Compliance Officer
- Jeff Pott General Counsel